Age-Related Macular Degeneration Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Disease Overview

Age-related macular degeneration is a disorder that causes loss of vision in a person due to macula damage; macula is that part of an eye, which helps a person to see, it is made up of millions of light-sensing cells which provide sharp and central vision. Age-related macular degeneration progresses slowly in an individual and can eventually lead to blindness. The most common symptom of Age-related macular degeneration is blurry vision. Age-related macular degeneration is common in people who are above the age of 50 years and is of two types namely, Dry Age-related macular degeneration and Wet Age-related macular degeneration. Dry Age-related macular degeneration is the most common form and almost eight out of ten Age-related macular degeneration patients suffer from this type of macular degeneration. Wet Age-related macular degeneration is less common, but is a more serious condition as compared to Dry Age-related macular degeneration. Various companies are developing drugs with promising targets for the treatment of the disease. Targeted therapy is more efficient in achieving good results. The potential targets are expected to possibly stop or slow down the progress of the disease with better efficacy and less side effects. The continuous efforts by various companies to find better and new treatment strategies with potential targets such as mitogen-activated protein kinase, complement factor D, retinal pigment epithelium cell, signal transducer and activator of transcription 3 (STAT3), also prove to be effective in treating Age-related macular degeneration.

Pipeline Analysis

As of May 2017, the Age-related macular degeneration pipeline comprises of approximately 55 drug candidates in different stages of development.

NUMBER OF AGE-RELATED MACULAR DEGENERATION THERAPEUTICS UNDER DEVELOPMENT(2017)

Competitive Landscape

Some of the key players developing drugs for the treatment of Age-related macular degeneration include Formycon, AG, Allergan Plc, Hoffmann-La Roche and others.

Scope for Customization

P&S Intelligence offers customization as per specific business requirements of clients. Illustrative customization within the scope of this report includes:

• Market Forecast – Market analysis and forecast for the drug candidates in the latest stage of development
• Company Profiles – Wider company coverage in terms of detailed analysis or additional company profiles